The 10-Minute Take podcast provides insights from RBC economists and market experts on events unfolding around the globe.
Featuring Brian Abrahams, RBC’s Co-Head of Biotechnology Research
The race is on for vaccines and treatments for COVID-19. Brian Abrahams, RBC’s Co-Head of Biotechnology Research, has some hope based on what he’s seeing but cautions we’re “in the early innings.” A vaccine is probably not realistic before 2021, he warns. And treatments – antivirals and anti-inflammatories, especially – could be months away. The efficacy of treatments could also vary widely across populations, just as we’re seeing with the virus. A magic bullet for curing coronavirus “is probably wishful thinking.” Even so, the availability of treatments, along with other measures, may slow infections, reduce their severity and enable some return to normalcy.
Click here to listen to more The 10-Minute-Take podcast episodes.
‡ For relevant conflicts disclosure, please visit our Disclosure Lookup Tool.
This article is intended as general information only and is not to be relied upon as constituting legal, financial or other professional advice. A professional advisor should be consulted regarding your specific situation. Information presented is believed to be factual and up-to-date but we do not guarantee its accuracy and it should not be regarded as a complete analysis of the subjects discussed. All expressions of opinion reflect the judgment of the authors as of the date of publication and are subject to change. No endorsement of any third parties or their advice, opinions, information, products or services is expressly given or implied by Royal Bank of Canada or any of its affiliates.